Physician

Molly Beth Chartier, M.D.

According to 2025 Medicare claims, Molly Chartier, M.D. (NPI: 1922245471) practices dermatology in the Rockingham County-Strafford County, NH market, with the plurality of this provider's patient population coming from Rockingham, NH. This provider's primary affiliated billing organization is NORTHEAST DERMATOLOGY ASSOCIATES, PC (NPI: 1508061839; TIN: 043138013) and primary practice location at 03833-4807.

Chartier's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,665 traditional Medicare patients, billed 9,718 HCPCS/CPT codes, and received $387,243 in Medicare payments. The top billing code was 17110 (Destruction of skin growth, 1-14 growths). Part D data shows 1,604 prescription claims across 615 beneficiaries totaling $923,164 in drug costs, led by Skyrizi Pen (Risankizumab-Rzaa). Open Payments data shows 95 records totaling $1,870. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $106,971 to $923,164. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$195K$389K2015 Medicare payment: $289,149 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $342,903 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $313,373 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $338,244 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $346,295 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $319,135 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $292,519 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $332,291 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $389,134 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $387,243 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20151,2977,525$289,149
20161,5689,093$342,903
20171,4538,760$313,373
20181,6389,275$338,244
20191,6579,669$346,295
20201,5778,822$319,135
20211,4447,540$292,519
20221,5288,102$332,291
20231,5949,294$389,134
20241,6659,718$387,243

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$462K$923K2015 Drug cost: $106,971 (USD; Tot_Drug_Cst)2016 Drug cost: $201,771 (USD; Tot_Drug_Cst)2017 Drug cost: $297,692 (USD; Tot_Drug_Cst)2018 Drug cost: $426,645 (USD; Tot_Drug_Cst)2019 Drug cost: $551,328 (USD; Tot_Drug_Cst)2020 Drug cost: $386,233 (USD; Tot_Drug_Cst)2021 Drug cost: $557,435 (USD; Tot_Drug_Cst)2022 Drug cost: $554,617 (USD; Tot_Drug_Cst)2023 Drug cost: $657,094 (USD; Tot_Drug_Cst)2024 Drug cost: $923,164 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015319673$106,971
2016394859$201,771
2017355871$297,692
2018401947$426,645
20194731,034$551,328
20204951,152$386,233
20214881,208$557,435
20224571,140$554,617
20235061,265$657,094
20246151,604$923,164

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
17110Destruction of skin growth, 1-14 growths225247$77
11102Biopsy of related skin growth, first growth530609$67
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more1,4251,916$58
17000Destruction of precancer skin growth, 1 growth9421,250$38
17003Destruction of precancer skin growth, 2-14 growths6853,624$5

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Skyrizi PenRisankizumab-Rzaa191,484$407,310
Cosentyx Sensoready (2 Pens)Secukinumab13364$108,200
OtezlaApremilast20600$96,159
Dupixent SyringeDupilumab14392$52,173
Dupixent PenDupilumab11294$42,189

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.95$1,870ABBVIE INC.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Molly Beth Chartier, M.D.?

Tedicare shows public-source Medicare data for Molly Beth Chartier, M.D. (NPI 1922245471), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Molly Beth Chartier, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Molly Beth Chartier, M.D.?

Molly Beth Chartier, M.D. is linked to NORTHEAST DERMATOLOGY ASSOCIATES, PC (billing NPI 1508061839) in the available physician profile data.

Does Molly Beth Chartier, M.D. have Open Payments data?

Molly Beth Chartier, M.D. has 95 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.